Forte Biosciences, Inc. (FBRX)
FBRX · Pharmaceutical Preparations · Dallas, TX · filing with the SEC since 2007
Filings
422 filings since 2017 beside 225 insider forms · Non-accelerated filer and smaller reporting company · read from EDGAR on Nov 13, 2026Due nextNon-accelerated filer and smaller reporting company
10-Q
Quarterly report for the quarter ending Sep 30, 2026Non-accelerated filers and smaller reporting companies have 45 days after the quarter ends; quarter ends are taken to the month end.
by Nov 14, 2026
10-K
Annual report for the fiscal year ending Dec 31, 2026Non-accelerated filers and smaller reporting companies have 90 days after the fiscal year ends.
by Mar 31, 2027
A deadline is the latest date the SEC's rules allow for its filer category. It is not a forecast of the day the company files. The proxy statement was last filed Apr 29, 2026.
Filings a yearinsider forms included
49693465846163108
2026 counts to Nov 13, 2026.
Listing warning from its exchange (8-K item 3.01): 1 time in the last 36 months, the newest Aug 27, 2026.Officer or director change (8-K item 5.02): 5 times in the last 36 months, the newest Aug 27, 2026.Auditor change (8-K item 4.01): 1 time in the last 36 months, the newest Dec 8, 2023.SEC letters: 4 in the last 36 months, the newest Apr 1, 2025.
Insider forms (3, 4, 5 and 144) are counted each year but not listed here; the people and their trades are on the Ownership tab.
FiledFormWhat it is, in plain wordsPeriodAsk
Aug 27, 2026
8-K items 2.01, 3.01, 3.03, 5.01, 5.02, 5.03, 9.01
Purchase or sale of a business completed; Listing warning from its exchange; Change to shareholders' rights; Change of control; Officer or director change; Charter, bylaw or fiscal-year change · Current report
40 of 422 shown
Every row opens the filing on EDGAR. The plain words are the site's own for each form and each 8-K item; the complete history, insider forms included, is on EDGAR.